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the SP-B peptides. In vivo ,  SP-B 1–25  and Ser-SP-B 1–25  increased 
the uptake by AM whereas dSP-B 1–25  decreased the uptake. 
Neither SP-B 1–25  nor dSP-B 1–25  affected total uptake by ATII. 
The overall uptake by SP-B 63–78  variants was not changed. 
 Conclusions: Surface-active synthetic SP-B peptides do not 
interfere with the normal  uptake of surfactant by ATII. 
 Copyright © 2007 S. Karger AG, Basel 
 Introduction 
 Pulmonary surfactant is essential for normal lung 
function, and its absence leads to respiratory failure. The 
presence of endogenous surfactant in the lung is depen-
dent upon a very complex system of production, secre-
tion, formation of lipid monolayer, turnover, re-uptake 
and recycling. Briefly, after secretion, surfactant unfolds 
to tubular myelin that is incorporated into the lipid 
monolayer. During respiration the surfactant in the lipid 
monolayer is turned over from large surface active aggre-
gates into small inactive surfactant aggregates  [1–3] . 
These small aggregates are removed from the alveolar 
space by both alveolar macrophages and alveolar type II 
cells. As de novo synthesis is insufficient to compensate 
the loss of surfactant, especially in neonates, the alveolar 
type II cells recycle these small aggregates.
 The uptake of small aggregates is influenced by sev-
eral factors, such as environmental ones  [4] , lipid consti-
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 Abstract 
 Background: Exogenous surfactant has been accepted 
worldwide as a therapy of RDS in premature and term in-
fants. Exogenous surfactant is usually derived from lung ex-
tracts containing phospholipids and the surfactant proteins 
SP-B and SP-C. Synthetic peptides of SP-B and SP-C are being 
tested with the aim to develop a completely synthetic sur-
factant preparation. Nevertheless, the effects of these pep-
tides on the endogenous surfactant metabolism remain un-
known.  Objectives: The effect of synthetic SP-B peptides on 
uptake of surfactant-like liposomes was investigated in al-
veolar cells. Native SP-B and seven SP-B peptides were in-
cluded: monomeric and dimeric SP-B 1–25  (Cys-11  ] Ala-11), 
SP-B 63–78   and Ala-SP-B 63–78  (Cys-71  ] Ala-71;Cys-77  ] Ala-
77)  and their serine mutants.  Methods: In vitro , alveolar 
macrophages (AM) and alveolar type II cells (ATII) were incu-
bated with liposomes containing SP-B or one of its peptides. 
In vivo ,  rats received intratracheally various SP-B peptides 
(SP-B/lipid ratio 1:  33 w/w) incorporated in fluorescent sur-
factant-like liposomes. One hour after instillation, AM and 
ATII were isolated and cell-associated fluorescence was de-
termined using flow cytometry. Confocal laser microscopy 
was performed to ensure internalization of the liposomes. 
 Results: In vitro uptake by AM or ATII was not influenced by 
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tution and surfactant proteins, mainly SP-A, SP-B and 
SP-C. Especially SP-A and to a smaller extent SP-C have 
been demonstrated to stimulate the uptake of surfactant 
lipids by alveolar type II cells and macrophages  [5–13] . 
However, the effects of SP-B on lipid uptake are more 
complex. SP-B can increase the uptake of liposomes in 
vitro  [10, 14–17] , but also inhibit SP-C mediated uptake 
by alveolar type II cells  [9, 10] .
 Exogenous surfactant has been accepted worldwide as 
a therapy of RDS in premature and term infants, and the 
use of surfactant therapy for adults is under discussion. 
Exogenous surfactant is usually derived from lung ex-
tracts containing phospholipids and the two hydrophobic 
surfactant proteins SP-B and SP-C; both these surfactant 
proteins play an important role in the surface tension 
lowering properties of surfactant  [18–20] . Moreover, the 
need of the two proteins is emphasized by the fact that 
absence of SP-B is lethal  [21, 22] . Synthetic peptides of
SP-B and SP-C based on the known human amino acid 
sequence are being tested with the aim to develop a com-
pletely synthetic surfactant preparation. Nevertheless, 
the effects of the surfactant proteins on the endogenous 
surfactant metabolism remain unknown.
 Our laboratory has been able to formulate and synthe-
size SP-B and SP-C peptides, which closely mimic the 
function of natural surfactant proteins  [23] . The in vivo 
metabolism and the effects on the clearance of these sur-
factant peptides have not yet been investigated. There-
fore, we studied the effect of monomeric and dimeric SP-
B 1–25  peptides, based on the N-terminal segment of hu-
man SP-B with an alanine for cysteine substitution at 
position 11, and SP-B 63–78 , based on the C-terminal of hu-
man SP-B, as well as various mutants of these peptides, 
on the uptake of surfactant-like liposomes by alveolar 
type II cells and alveolar macrophages. The SP-B 1–25  (Cys-
11  ] Ala-11) variant disulfide linked homodimer has 
been the focus of recent laboratory studies as it closely 
mimics the in vitro and in vivo functions of the full-
length SP-B protein  [24–26] .
 Materials and Methods 
 Ethical Guidelines 
 The Institutional Animal Care and Use Committee at the 
Erasmus MC–Faculty Rotterdam, approved this study.
 Native SP-B and Synthetic SP-B Peptides 
 Native SP-B was isolated from porcine lung lavage and char-
acterized according to standard procedures  [27] . Monomeric SP-
B 1–25  peptide was synthesized on a 0.25-mmol scale with a peptide 
synthesizer (Applied Biosystems Model 431A) using a FastMoc TM  
strategy  [28] . The SP-B 1–25  sequence was based on the N-terminal 
of human SP-B  [29] with one modification, cysteine in position 
11 was replaced by alanine (Cys-11  ] Ala-11 variant monomer) 
 [24, 25] . The SP-B 63–78  sequence was based on the C-terminal of 
human SP-B  [29] without modification (SP-B 63–78 ) or with substi-
tutions of alanine for cysteine in positions  71 (Cys-71  ] Ala-71) 
and 77 (Cys-77 ] Ala-77)  in Ala-SP-B 63–78 . The peptides were 
synthesized with prederivatized Fmoc-Gly resin (Calbiochem-
Nova, La Jolla, Calif., USA) or PEG-PA resin (Perceptive Biosys-
tems, Old Connecticut Path, Mass., USA) and single coupled for 
all residues. After purification by reverse-phase high performance 
liquid chromatography, the molecular mass was confirmed by fast 
atom bombardment mass spectroscopy or electrospray mass 
spectroscopy  [29] . The SP-B 1–25  (Cys-11  ] Ala-11) variant disul-
fide linked homodimer was formed by oxidizing the monomeric 
SP-B 1–25  peptide (SP-B 1–25 )  [24, 25] . The molecular mass of this 
dimeric SP-B 1–25  peptide (dSP-B 1–25 ) was confirmed by electro 
spray mass spectroscopy and indicated the yield of dimeric prod-
uct to be essentially 100%  [24] .
 Mutant monomeric and dimeric SP-B 1–25  peptides were syn-
thesized with site-specific substitutions of serine for arginine in 
positions 12 and 17 and for lysine in positions 16 and 24 of the N-
terminal ( fig. 1 ). Mutant SP-B 63–78  peptide was synthesized with 
site-specific substitutions of serine for arginine in positions 64, 
72, and 76 of the C-terminal ( fig. 1 ) These site-specific substitu-
tions reduce the net cationic charge on the molecule without af-
fecting the hydrophobicity  [23] . Synthesis, purification and char-
acterization of the serine mutants were done in the same manner 
as the original peptides.
 Liposome Preparation 
 Liposomes were prepared by mixing the following lipids in 
chloroform:methanol (1:  1; v:v); dipalmitoylphosphatidylcholine 
SP-B63–78
Gly-Arg-Met-Leu-Pro-Gln-Leu-Val-Cys-Arg-Leu-Val-Leu-Arg-Cys-Ser
Ser-SP-B63–78
Gly-Ser-Met-Leu-Pro-Gln-Leu-Val-Cys-Ser-Leu-Val-Leu-Ser-Cys-Ser
Ala-SP-B63–78
Gly-Arg-Met-Leu-Pro-Gln-Leu-Val-Ala-Arg-Leu-Val-Leu-Arg-Ala-Ser
SP-B1–25
Phe-Pro-Ile-Pro-Leu-Pro-Tyr-Cys-Trp-Leu-Ala-Arg-Ala-Leu-Ile-Lys-Arg-
Ile-Gln-Ala-Met-Ile-Pro-Lys-Gly
Ser-SP-B1–25
Phe-Pro-Ile-Pro-Leu-Pro-Tyr-Cys-Trp-Leu-Ala-Ser-Ala-Leu-Ile-Ser-Ser-
Ile-Gln-Ala-Met-Ile-Pro-Ser-Gly
 Fig. 1. Peptide sequences of the SP-B peptides and their serine 
mutants. The SP-B 1–25  homodimer consists of two SP-B 1–25  mono-
mers which are disulfide-linked at Cys8. 
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(DPPC), egg  phosphatidylcholine (PC), egg  phosphatidylglycerol 
(PG), soybean  phosphatidylinositol (PI), and phosphatidyl etha-
nolamine (PE) labeled with Texas red in the head group (Texas 
Red DHPE, Molecular Probes Inc., Leiden, The Netherlands), 
cholesterol in a weight ratio of 55:  21:  8:2:  6:8 and the indicated sur-
factant proteins at a protein/lipid concentration of 3:  100 w:w. 
Subsequently, this mixture was dried under a stream of nitrogen. 
The lipids were purchased from Sigma (Zwijndrecht, The Neth-
erlands), unless stated otherwise. The liposomes were suspended 
in PBS, pH 7.4 ,  at a concentration of 0.5 mg lipids/ml (in vitro ex-
periments) or 1 mg/ml (in vivo experiments) using glass pearls 
and vortexing. Immediately prior to use, the liposome suspension 
was sonicated for 2 min on ice using an ultrasonic disintegrator 
(Branson Sonifier 250, Danbury, Conn., USA) to prepare small 
unilamellar liposomes  [4] . The size of the liposomes was deter-
mined by dynamic light scattering at 25  °  C with a Malvern 4700 
system using a 25 mW He-Ne laser (NEC, Tokyo, Japan) and the 
auto measure version 3.2 software (Malvern Ltd., Worcestershire, 
UK). As a measure of particle size distribution of the dispersion, 
the system reports a polydispersity index (p.d.). This index rang-
es from 0.0 for a monodisperse and up to 1.0 for an entirely poly-
disperse dispersion. After ultrasonification the liposome size 
ranged from 140 to 165 nm and the polydispersity index ranged 
from 0.2 to 0.35.
 Intratracheal Instillation of Fluorescent Liposomes 
 The studies were performed with male Sprague-Dawley rats 
(IFFA Credo, The Netherlands) with a bodyweight of 318  8 16 g. 
After induction of anesthesia with a mixture of nitrous oxide 
(66%), oxygen (33%) and isoflurane (1–2%), a sterile polyethylene 
catheter (0.8 mm o.d.) was inserted into one of the carotid arter-
ies. The animals were then tracheotomized and a sterile metal 
cannula was inserted into the trachea. After these surgical proce-
dures, the animals were mechanically ventilated as described  [4, 
30, 31] . After disconnection from the ventilator, the liposomes 
were administered intratracheally at the indicated dosage. The 
suspension of liposomes (1 mg lipids/ml) was administered as a 
bolus of 3 ml/kg followed by a bolus of air (12 ml/kg), directly into 
the endotracheal tube via a syringe, and the animals were imme-
diately reconnected to the ventilator. After 1 h of ventilation the 
animals were sacrificed by exsanguination via the abdominal aor-
ta and the alveolar type II cells and alveolar macrophages were 
isolated to determine the cell-associated fluorescence. Untreated 
animals were sacrificed immediately after anesthesia and their 
isolated alveolar type II cells and alveolar macrophages were used 
to correct for auto-fluorescence.
 Isolation of Alveolar Type II Cells and Alveolar Macrophages 
 The alveolar type II cells and alveolar macrophages were iso-
lated as described  [4, 30, 31]  and suspended in cell-buffer (140 m M 
NaCl, 5 m M KCl, 2.5 m M Na 2 HPO 4   2H 2 O, 10 m M HEPES, 6 m M 
glucose, 2.0 m M CaCl 2  and 1.3 m M MgSO 4 ) at concentrations of 
2  ! 10 6  cells/ml and stored on ice until further use.  Alveolar mac-
rophages were identified using monoclonal antibodies specific for 
rat macrophages (ED9) and alveolar type II cells were identified 
using an alkaline phosphatase assay as described by Edelson et al. 
 [32] . The average yield of alveolar type II cells was 16  ! 10 6  with 
a purity of 80  8 5% and 5  ! 10 6  alveolar macrophages with a 
purity of 92  8 5% per rat.
 In vitro Uptake of SP-B Peptides 
 Alveolar cells of untreated animals were isolated as described 
above and suspended in cell buffer to a concentration of 2  ! 10 6  
cells/ml. A total of 3  ! 10 5  cells were incubated with the indi-
cated concentration of the specified liposomes at 37  °  C (final vol-
ume 500   l) in a shaking water bath. After 1 h, the incubation was 
terminated by addition of 2 ml of ice-cold PBS (4  °  C). The cell-
suspension was centrifuged at 100  g for 10 min at 4  °  C. The super-
natant was removed, and the cells were suspended in 2 ml ice-cold 
PBS and centrifuged again. This wash procedure was repeated 
twice. Finally, the pellet was resuspended in 200   l of cold PBS, 
and cell-associated fluorescence was determined as described 
 below.
 Flow Cytometry 
 Cell-associated fluorescence of the alveolar type II cells and 
alveolar macrophages as a measure for internalized liposomes 
was determined using flow cytometry (FACSCalibur; Becton 
Dickinson, Mountain View, Calif., USA). The mean cell-associ-
ated fluorescence was determined of all the cells, including the 
cells, which did not internalize the fluorescent liposomes. In ad-
dition, the mean cell-associated fluorescence was determined of 
the cells with a fluorescence higher then the autofluorescence 
(Mean cell-associated fluorescence of gated cells) as described be-
fore  [4, 30, 31] .
 Localization of Cell-Associated Fluorescence 
 To localize the cell-associated fluorescence, intracellular or 
extracellular, confocal laser micrographs were obtained using a 
confocal microscope (LSM510NLO, Carl Zeiss, Jena, Germany) 
as described  [4, 30, 31] .
 Statistical Analysis 
 Differences between the groups that received liposomes with 
a different composition were analyzed using an ANOVA followed 
by a Bonferroni post-hoc test. Blood gas values were analyzed us-
ing a repeated measurement ANOVA. Differences were consid-
ered statistically significant at a p  ! 0.05. Values are expressed as 
mean  8 SEM.
 Results 
 Effect of SP-B 1–25  on the Uptake of Liposomes by 
Alveolar Cells in vitro 
 After isolation from untreated animals, alveolar cells 
were incubated with different concentrations of lipo-
somes. In these liposomes, native SP-B (dSP-B), SP-B 1–25  
or dSP-B 1–25  was included in a protein to lipid ratio of
3:  100. After 1 h the incubation was stopped and cell-as-
sociated fluorescence was determined.
 The incorporation of SP-B (or derivations) in the fluo-
rescent-labeled liposomes did not influence the uptake of 
these liposomes by alveolar cells ( fig. 2 a, c). Nor was the 
percentage of cells involved in the uptake affected by the 
inclusion of proteins in the liposome ( fig. 2 d).
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 Effect of SP-B Peptides Containing Liposomes on Gas 
Exchange 
 The inclusion of SP-B 1–25  and SP-B 63–78  peptides in the 
labeled liposomes did not affect gas exchange. Arterial 
blood gas values remained at healthy levels after instilla-
tion (results not shown).
 Effect of SP-B Peptides on the Uptake by Alveolar 
Cells in vivo 
 To study the effect of the various SP-B  peptides on the 
liposome uptake by the alveolar cells, the peptides were 
incorporated in fluorescent-labeled liposomes at a pro-
tein to lipid concentration of 3:  100 w:w. The mean cell-
associated fluorescence of the gated alveolar cells, the al-
veolar cells which had internalized the fluorescent lipo-
somes, was significantly higher when either dSP-B 1–25  or 
SP-B 63–78  was included in the labeled liposomes suggest-
ing more uptake of these liposomes by the cells ( fig. 3 a). 
However, the number of alveolar type II cells involved in 
the uptake when dSP-B 1–25  was incorporated in the lipo-
somes was significantly reduced ( fig. 3 b).Also a reduc-
tion of the number of cells internalizing SP-B 63–78  con-
taining liposomes was observed, though not significant. 
Overall, the mean uptake of the liposomes by the alveolar 
type II cells was not affected by the incorporation of SP-B 
or SP-B peptides in the liposomes ( fig. 3 a).
 The uptake of liposomes by alveolar macrophages is 
more influenced by the inclusion of SP-B peptides in the 
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 Fig. 2. Effect of dSP-B, SP-B 1–25  and dSP-B 1–25  on the alveolar cell 
uptake in vitro. Alveolar cells were isolated from untreated ani-
mals and incubated for 1 hour at 37  °  C with the indicated concen-
trations of fluorescent liposomes dependent on the group con-
taining native SP-B (dSP-B), monomeric SP-B 1–25  (SP-B 1–25 ) or di-
meric SP-B 1–25  (dSP-B 1–25 ) or no proteins (normal). The SP-B 
proteins were included in a protein to lipid ratio of 3:100. The 
mean cell-associated fluorescence of gated alveolar type II cells 
(a) and alveolar macrophages (c) was determined. In addition, the 
percentage gated alveolar type II cells (b) and alveolar macro-
phages (d) were determined. No significant differences were ob-
served at any concentration (n = 4 incubations at every concentra-
tion; values are mean  8 SEM). 
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liposome. Incorporation of mono or dimer SP-B  1–25,  Ser-
SP-B 1–25 , SP-B 63–78  and Ala-SP-B 63–78  enhanced the up-
take of the liposomes by the gated cells ( fig. 3 c). The per-
centage alveolar macrophages taking part in the uptake 
was significantly decreased with the inclusion of mono or 
dimer SP-B 1–25,  SP-B 63–78  and Ala-SP-B 63–78  in the lipo-
somes ( fig. 3 d). In contrast to the alveolar type II cells, 
the total uptake by all the alveolar macrophages was in-
fluenced by the SP-B peptides. SP-B 1–25  and Ser-SP-B 1–25  
stimulated and dSP-B 1–25  inhibited the uptake ( fig. 3 c).
 Localization of Cell-Associated Fluorescence Caused 
by SP-B 1–25  
 To ascertain that the cell-associated fluorescence was 
located within the cell rather than binding to the outer 
membrane of the cell, confocal laser scanning micros-
copy was used. One hour after intratracheal instillation 
of the liposomes containing SP-B 1–25  or dSP-B 1–25  in ven-
tilated rats, the alveolar cells were isolated and confocal 
scans were made. These confocal scans through the mid-
dle of the cell show a punctuate fluorescence throughout 
the cell limited to its circumference with the exception of 
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 Fig. 3. Effect of SP-B and its peptides on the uptake of liposomes 
by alveolar cells in vivo. Fluorescent labeled liposomes with no 
proteins (Normal), native SP-B (dSP-B), monomeric SP-B 1–25  (SP-
B 1–25 ), dimeric SP-B 1–25  (dSP-B 1–25 ), Ser-SP-B 1–25 , Ser-dSP-B 1–25 , 
monomeric SP-B 63–78  (SP-B 63–78 ), Ser-SP-B 63–78  or Ala-SP-B 63–78  
incorporated at a protein to lipid ratio of 3:100 were intratrache-
ally instilled in ventilated rats. After one hour, alveolar type II 
cells (a, b) and alveolar macrophages (c, d) were isolated. The 
mean cell-associated fluorescence of all the cells was determined 
(all cells, closed bars; a, c) as well as the mean cell-associated flu-
orescence of those cells with a higher fluorescence then the auto-
fluorescence (gated cells, open bars; a, c). In addition, the number 
of cells was measured with a higher fluorescence then the auto-
fluorescence (gated cells [%]; b, d) (n = 4 rats per group; values are 
mean  8 SEM);  * p  ! 0.05 versus normal; ** p ! 0.05 versus nor-
mal (total fluorescence). 
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its nucleus, demonstrating the intracellular presence of 
the fluorescent liposomes ( fig. 4 ); although these figures 
suggest a different uptake or distribution, because there 
are differences in density of luminance and size of the 
granulae no definite conclusion can be drawn from the 
current experiments. Similar results were obtained with 
mono and dimer Ser-SP-B 1–25  (results not shown).
 Discussion 
 SP-B is essential for the biophysical properties of pul-
monary surfactant. SP-B is a 79 amino acid, cysteine-rich 
hydrophobic protein found in pulmonary surfactant as 
an 18-kDa dimer. It is synthesized in the endoplasmic re-
ticulum of the alveolar type II cell as a large precursor 
protein of 42 kDa. This precursor SP-B is transported via 
the Golgi complex and the multivesicular bodies to the 
lamellar bodies while it undergoes proteolytic processing 
to the mature 9-kDa protein. In the lamellar bodies SP-B 
combines with the other surfactant proteins and lipids. 
The lamellar bodies are secreted into the alveolar space, 
where they provide functional surfactant for the air-wa-
ter interface. The surfactant metabolism in vivo  has re-
cently been reviewed  [33] . In the adult lung SP-B is cleared 
more rapidly from the alveoli than saturated phosphati-
dylcholine  [34] . In the developing lung, the clearance of 
phospholipids and SP-A is in general much slower than 
in the adult lung  [35, 36] . The clearance of SP-A, B,
and C has been studied in adult (rabbit) lungs  [34, 35, 37] , 
 Fig. 4. Localization of cell-associated fluorescence of SP-B 1–25 .  Mechanically ventilated rats were intratrache-
ally instilled with fluorescent labeled liposomes containing either SP-B 1–25  (a, c) or d-SP-B 1–25  (b, d). One hour 
after instillation alveolar macrophages (c, d) and alveolar type II cells (a, b) were isolated and confocal scans 
were made. All scans were made using the same microscopic settings. 
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the clearance of SP-B in newborn rabbits  [38] and that of 
SP-C in preterm lambs  [39] . The surfactant proteins are 
not only cleared from the alveolar space but may also play 
a role in the clearance of surfactant lipids from the alveo-
lar space. Both SP-A and SP-C have been shown to stim-
ulate the uptake. The effects of SP-B are more complex, at 
physiological amounts it does not affect uptake though at 
high concentrations SP-B stimulates the clearance of la-
beled liposomes  [31] .
 In our laboratory, synthetic peptides of SP-B have been 
designed, and their function in lowering surface tension 
has been demonstrated  [24] . However, the effects of these 
synthetic SP-B peptides on the clearance are not yet clar-
ified. In the current study the effect of the incorporation 
of SP-B peptides on the uptake of labeled liposomes was 
studied both in vivo and in vitro.
 First, the effects of the synthetic SP-B fragments on the 
uptake of labeled liposomes were studied in vitro and af-
ter comparison with native SP-B, it can be concluded that 
the incorporation of 3% SP-B or SP-B peptides does not 
influence the uptake by alveolar cells nor the percentage 
of cells involved in the uptake. However, significant dif-
ferences between in vitro and in vivo studies have been 
demonstrated, and thus similar experiments were per-
formed in vivo.
 For alveolar type II cells the overall clearance of lipo-
somes was the same irrespective of the SP-B peptides it 
contained. However, individual differences were observed 
in the two components of the total uptake: (1) the mean 
fluorescence of the gated cells, and (2) the number of cells 
involved in the uptake. For instance, inclusion of either 
dSP-B 1–25  or SP-B 63–78  enhanced the mean uptake of the 
gated cells whereas the number of gated cells was reduced. 
Only 30% of the isolated type II cells contained liposomes 
as was observed before  [4] . It is possible that there are lo-
cal factors which influence the uptake of liposomes by the 
type II cells or that there are different sub-populations of 
type II cells in vivo  [4] . A population of approximately 
30% of type II cells which can internalize liposomes. This 
population can vary a little dependent on the composition 
of the liposome. In vitro, many more type II cells can in-
ternalize liposomes and the peptides did not influence the 
uptake. A possible explanation for the differences in vivo 
and in vitro is that the uptake of liposomes by the alveolar 
type II cells is tightly regulated by cells or components of 
the alveolar compartment in vivo as we postulated before 
 [4, 40] . Also for alveolar macrophages the uptake of lipo-
somes in vitro and in vivo was different. In vitro, the in-
clusion of SP-B or the SP-B  peptides in the liposomes did 
not influence the uptake. In vivo, all the peptides, except 
Ser-SP-B 63–78  and Ser-SP-B 1–25 , enhanced the uptake of 
the liposomes per gated cell. The number of cells involved 
in the uptake was reduced when mono or dimer SP-B 1–25 , 
SP-B 63–78  or Ala-SP-B 63–78  were included in the liposome. 
SP-B 1–25  and Ser-SP-B 1–25  enhanced the total uptake by the 
alveolar macrophages whereas d-SP-B 1–25  reduced it.
 Unfortunately, a simple relation between the structure 
of the SP-B peptides and the uptake of liposomes contain-
ing these peptides by the alveolar cells cannot be demon-
strated.  SP-B 1–25  contains an Ala for Cys-11 substitution 
resulting in a more saposine-like fold which is present in 
the native full-length SP-B structure  [40] . It seems un-
likely that the saponine-like fold plays a crucial role in the 
uptake, since SP-B 1–25  and native SP-B both have the sa-
posine fold but have a different effect on the uptake. Also 
alterations in the cationic charge of SP-B by the substitu-
tions of either serine for arginine and lysine or alanine for 
cysteine, the mono or dimer form of the peptides and the 
N-terminus or C-terminus of SP-B, do not by themselves 
govern the uptake of the liposomes. More studies are 
therefore required to determine the exact mechanism by 
which the SP-B peptides influence the uptake of lipo-
somes by alveolar cells as well as the intracellular route of 
the liposomes.
 These synthetic surfactant proteins, based on human 
native SP-B were developed with the aim to produce a 
completely synthetic surfactant. Charge of the SP-B pep-
tides, mono or dimeric form, the saponine-like fold were 
shown to influence the surface-lowering properties of 
surfactant as well as its resistance to inactivation by se-
rum components  [40] . The results of the current study 
indicate that native SP-B and its peptides tested had no 
effect on the overall uptake of liposomes by alveolar type 
II cells, an important aspect of the surfactant metabo-
lism. Therefore, as far as the uptake is concerned, there 
seems to be no preference of one particular peptide over 
the other to use in synthetic surfactant. However the 
clearing of the SP-B peptides by alveolar macrophages, 
which may determine the half-life of these peptides in the 
alveoli, is influenced by the structure of the SP-B pep-
tides. Turnover studies using the different SP-B peptides 
are required to determine how long the peptides stay in 
the alveolar compartment.
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